Editas Medicine

General Information

We are a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. We believe that we have entered a new era of genomic medicine as the growth of genomic information in recent decades has significantly expanded the understanding of genetically defined diseases. A new technology known as CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) has the potential to achieve precise, directed changes in DNA.

Employees: 55
Founded: 2013
Contact Information
Address 300 Third Street, First Floor, Cambridge, MA 02142, US
Phone Number (617) 401-9000
Web Address http://www.editasmedicine.com
View Prospectus: Editas Medicine
Financial Information
Market Cap $571.2mil
Revenues $0.0 mil (last 12 months)
Net Income $-65.7 mil (last 12 months)
IPO Profile
Symbol EDIT
Exchange NASDAQ
Shares (millions): 5.9
Price range $16.00 - $16.00
Est. $ Volume $94.4 mil
Manager / Joint Managers Morgan Stanley/ J.P. Morgan
CO-Managers Cowen and Company/ JMP Securities
Expected To Trade: 2/3/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change